Skip to main content

Nasdaq Markets

Why Shares of Niu Technologies Skyrocketed 37% in October

6 years ago
What happenedRebounding from a 7% drop in September, shares of Niu Technologies (NASDAQ: NIU) climbed 37%, according to data from S&P Global Market Intelligence. In addition to the company's reporting of third-quarter sales, investors were motivated to pick up shares of the C

What Is Ollie's Bargain Outlet's Biggest Competitive Edge?

6 years ago
Bargain-price retail isn't the easiest industry to survive within, much less prosper. Successful chains need to hone a sharp competitive edge to sustain profit margin and feed top-line improvement. Motley Fool contributor Asit Sharma reveals the single competitive strength that's

Ollie's Bargain Outlet: Expansion Opportunities and Risks

6 years ago
Close-out merchandise specialist Ollie's Bargain Outlet (NASDAQ: OLLI) has a simple method for juicing revenue over the long term in addition to lifting comparable sales: Open more stores. Motley Fool contributor Asit Sharma and analyst Aurie Hughes discuss the potential for addi

3 Stocks to Watch This Week

6 years ago
This is a wild time for investors. The number of issues weighing on our finances is vast: the outcome of the U.S. presidential election, big changes to social security next year, COVID-19 cases rising into winter, and the list goes on and on. At the moment, these developments are

3 Moves to Ensure You're a Retirement Multi-Millionaire

6 years ago
The average worker estimates retirement will cost nearly $2 million, according to a survey from Charles Schwab.Although that might sound like an exorbitant amount of money, it may be a realistic goal -- especially when you consider that retirees are living longer, Social Security

Forget Ant Group: Consider This Chinese Fintech Instead

6 years ago
By now, most investors have heard about Ant Group, the Chinese fintech backed by Alibaba whose IPO was abruptly canceled this week. Investors did not see that coming and were left frustrated. Still, they can consider other listed companies to catch on to the fintech boom in China

Is BJ's Restaurants Stock a Buy?

6 years ago
BJ's Restaurants (NASDAQ: BJRI), a casual dining and beer establishment, has had a rough year. The stock price, which is down 18% in 2020, reflects this reality.Certainly, it is far from the only industry participant that has felt the pinch from these trying days. That raises the

ETF Strategies to Play as Coronavirus Outbreak Aggravates

6 years ago
The coronavirus outbreak continues to aggravate in the United States and globally. Making the situation worse are concerns that another round of business restrictions and lockdown measures might derail the economic recovery achieved so far.Consequently, investors are looking for

Where Will Netflix Be in 10 Years?

6 years ago
Netflix (NASDAQ: NFLX) helped usher in a new era of entertainment with streaming over the last 10 years, and the growth it has experienced has led to massive returns for investors.The thing is that it is still a relatively young company. It debuted its first original series in 20

3 Takeaways From Wendy's Q3 Earnings

6 years ago
On Nov. 4, Wendy's NASDAQ: WEN) reported fiscal third-quarter adjusted earnings per share of $0.19 on revenue of $452.2 million, above consensus earnings estimates of $0.17 but falling slightly short of expectations for $454.1 million of revenue. The top line was aided by strengt

Macerich Earnings: Signs of Stabilization Emerging

6 years ago
The year 2020 hasn't been kind to mall owners like Macerich (NYSE: MAC). Many malls were forced to close for months during the lockdown phase of the COVID-19 pandemic. Even after they reopened, traffic typically remained depressed, as many consumers are wary of crowded public spa

Goldman Sachs: These 2 Stocks Have the Potential to Rally Over 40%

6 years ago

Joe Biden will become the 46th president of the U.S., and Wall Street is rejoicing. Analysts have previously stated that regardless of the winner, the end of the election will reduce a significant amount of uncertainty, and potentially pave the way for stocks to move higher.  

Now, investors are waiting to see which party will gain control of the Senate, although it appears that the Republicans are in the lead. This is the favored outcome among investors as a divided government would take the more ambitious policies from either side out of the equation.  

Against this backdrop, five-star analyst Salveen Richter from investment firm Goldman Sachs is pounding the table on two stocks in particular, noting that each could surge over 40% in the year ahead.  

After running both tickers through TipRanks’ database, we found out that the rest of the Street is also standing squarely in the bull camp as each boasts a “Strong Buy” analyst consensus.  

Kronos Bio (KRON) 

First up we have Kronos Bio, which targets dysregulated transcription factors, or proteins that convert DNA to RNA, and their associated transcriptional regulatory networks (TRNs), which drive oncogenic activity. With several potential catalysts on the horizon, it’s no wonder Goldman Sachs thinks investors should get on board. 

Looking more closely at the approach, TRNs are a complex network of proteins that work to control gene expression programs, and whose interactions are bi-directional, interdependent and dynamic. When they are dysregulated, they can create an oncogenic state. 

“Despite the complicated interplay of TRNs (which has been historically difficult to characterize), KRON’s differentiated approach leverages its product engine for mapping of oncogenic TRNs to identify critical nodes (proteins, genes, or enzymatic substrates) that may be vulnerable to therapeutic intervention and uses the proprietary small molecule microarray (SMM) platform to identify potent and selective drug candidates against previously undruggable targets,” Richter explained. 

The biopharma’s immediate efforts center around its two lead programs, entospletinib (designed as an SYK inhibitor) and KB-0742 (its CDK9 inhibitor). To this end, Richter argues that several developments related to these assets could push shares higher. An end-of-Phase 2 meeting is slated for 1H21, with KRON set to discuss its plans for the pivotal trial design and endpoints for evaluating entospletinib in 1L NPM1+ AML patients with regulatory agencies. 

“We expect the key area of focus will be on the use of measurable residual disease (MRD) negative status as an acceptable endpoint for regulatory approval - we note prior precedents for its use in hematologic malignancies and evidence that NPM1 mutation absence is correlated with improved overall survival and relapse prevention in AML - thus we are optimistic on the path forward,” Richter mentioned. It should be noted that any decisions here will have “important implications on trial size and length of study,” in the analyst’s opinion. 

Additionally, now that IND-enabling studies have wrapped up, KRON is planning to submit an IND for KB-0742 in Q4 2020, meaning initiation of the Phase 1/2 dose escalation and expansion trial could come in 2021.  

Richter stated, “In our view, initial positive data will serve to partially de-risk KRON’s approach in identifying and targeting dysregulated transcription factors and provide confidence in the use of the SMM platform to differentially identify potent and selective inhibitors.” 

If that wasn’t enough, when the company kicks off the Phase 1/2 entospletinib trial in R/R FLT3+ AML in 2021 and it files the IND for one of its discovery programs in 2022, Richter believes there could be even more upside. Commenting on the latter, the analyst said, “We see the areas of focus as logical given synergies across programs (e.g. targeting MYB for AML or ARv7 for solid tumors/prostate cancer) and look to advancement of a third program to provide visibility into the portfolio outlook.” 

All of the above prompted Richter to initiate coverage with a Buy rating and $45 price target, suggesting 48% upside potential. (To watch Richter’s track record, click here) 

Are other analysts in agreement? They are. Only Buy ratings, 4 to be exact, have been issued in the last three months. Therefore, the message is clear: KRON is a Strong Buy. Given the $43.67 average price target, shares could rise 44% in the next year. (See Kronos Bio stock analysis on TipRanks) 

Allogene Therapeutics (ALLO) 

Focused on developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies, Allogene Therapeutics hopes to find the next immunologic breakthrough in cancer. Ahead of an upcoming data readout, Goldman Sachs likes what it’s seeing.  

According to Richter, investors are waiting for the first look at Phase 1 ALLO-715, its allogeneic CAR T cell therapy targeting BCMA, (UNIVERSAL) data in R/R multiple myeloma (MM). This data will be released as part of an ASH presentation. The Phase 1 UNIVERSAL trial is evaluating four dose levels of ALLO-715 and several lymphodepletion regimens, as well as ALLO-647 (its anti-CD52 antibody) 39 mg divided over three days. 

“As we have previously noted, if successful, alternative routes of lymphodepletion could introduce greater flexibility of administration (cy/flu lymphodepletion is generally carried out only at the academic centers that specialize in stem cell transplants) and could potentially be an important step towards advancing the allogeneic CAR T therapies to an outpatient clinic,” Richter told clients. 

Looking at the available clinical data, a dose-response with a 60% ORR was witnessed at dose level 3, with the ASH presentation potentially providing more clarity on dose level 4 and the benefit of a higher ALLO-647 dose within the preconditioning regimen. In one of the groups, one of the two responders was classified as having achieved a stringent complete response (sCR), with the other achieving a very good partial response (VGPR).  

That being said, Richter will be monitoring the tolerability profile as one of the patients developed a non-neutropenic fever and multifocal pneumonia following the ALLO-715 infusion, and progressed to respiratory failure, with the death tied to the preconditioning regimen. Additionally, four patients had Gr3+ infections, but management stated that elevated infection risk is consistent with the underlying medical condition.  

“We would note no changes to the trial protocol have been implemented with management maintaining confidence in the potential benefit of higher dose ALLO-647,” Richter said. 

On top of this, Richter argues the Phase 1 ALLO-501 (its allogeneic CAR T cell therapy targeting CD19) data in relapsed and refractory non-Hodgkin lymphoma (NHL), which is expected in 1H21, will “provide a more robust view of durability and optimization of levers (including repeat dosing), which alongside ALLO-501A (its CAR T cell therapy targeting CD19 devoid of the rituximab switch) dose escalation data, will inform the pivotal trial design (2021 start).” The IND filings for ALLO-715 plus Springworks Therapeutics’ nirogacestat in R/R MM and ALLO-316 (an anti-CD70 CAR T) in renal cell carcinoma are also on track for YE20. 

In line with her optimistic approach, Richter sides with the bulls, reiterating a Buy rating. She also bumped up the price target from $66 to $67. This new target conveys her confidence in ALLO’s ability to climb 141% higher in the next year.  

Most other analysts echo Richter’s sentiment. 8 Buys and 2 Holds add up to a Strong Buy consensus rating. With an average price target of $55.63, the upside potential comes in at 100%. (See Allogene Therapeutics stock analysis on TipRanks) 

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. 

Why First Solar Jumped 31.5% in October

6 years ago
What happenedShares of First Solar (NASDAQ: FSLR) rose 31.5% in October, according to data from S&P Global Market Intelligence. The U.S. solar panel manufacturer held its third quarter earnings report late in the month, blowing past analyst estimates, all while polling showed

3 Secrets Every Wealthy Investor Knows

6 years ago
Investing is like an art form: Each person has a lot of latitude to build a unique portfolio that reflects who they are and what they want. But there are still some basic principles that just about everyone follows.When it comes to investing, these principles can mean the differe

Why JinkoSolar Skyrocketed 46.6% in October

6 years ago
What happenedShares of JinkoSolar (NYSE: JKS) rocketed 46.6% higher in October, according to data from S&P Global Market Intelligence. The China-based solar panel manufacturer rose following strong earnings report released toward the end of September, then accelerated as poll

2 Cancer Stocks That Could Make You Filthy Rich

6 years ago
Developmental cancer companies can produce jaw-dropping returns on capital in short order. The core reason is that most of these companies are trading at a mere fraction of the commercial potential of their lead product candidates.That's not surprising, given that most anti-cance

Could You Live on $18,516 in Annual Retirement Income?

6 years ago
Most Americans count on Social Security to serve as a major source of retirement income. But while retirement benefits from the Social Security Administration will likely help you cover costs as a retiree, you can't rely on them too much, or you could find yourself facing a lot o
Checked
2 minutes 43 seconds ago
This feed is responsible for generating the rss feed related to the topic Markets
Subscribe to Nasdaq Markets feed